Core Points - A class action securities lawsuit has been filed against KBR, Inc. to recover losses for shareholders affected by alleged securities fraud between May 6, 2025, and June 19, 2025 [2][3] - The complaint alleges that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [3] - The lawsuit claims that KBR's statements about its business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [3] Next Steps - Shareholders who suffered losses in KBR, Inc. stock during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP is a nationally recognized securities litigation firm with a strong track record in securing recoveries for shareholders, having ranked in the Top 50 Report for seven consecutive years [5]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected shareholders between January 8, 2024, and September 17, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, which were unauthorized by the U.S. Food and Drug Administration [3]. - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The complaint asserts that the enhancements to the G7, along with its reliability, accuracy, and functionality, were overstated, and the true scope of the issues was downplayed [3]. Group 2: Implications - The alleged actions have subjected DexCom to increased regulatory scrutiny and potential enforcement actions, leading to significant legal, reputational, and financial harm [3]. - The public statements made by the defendants are claimed to have been materially false and misleading throughout the relevant period [3]. Group 3: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 4: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing substantial recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Did You Suffer Losses in Perrigo Company plc (PRGO)? Contact Levi & Korsinsky About Securities Fraud ClaimsNovember 13, 2025 3:32 PM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Perrigo Company plc ("Perrigo Company plc") (NYSE: PRGO) concerning possible violations of federal securities laws.Perrigo issued a press release on November 5, 2025, "announc[ing] that it is i ...

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, Incorporated, alleging securities fraud that affected shareholders between December 27, 2023, and May 6, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [3]. - Defendants indicated that they expected FDA approval for aficamten's NDA in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [3][4]. - During an earnings call on May 6, 2025, it was disclosed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [4]. Group 2: Impact on Shareholders - As a result of the alleged false statements, shareholders purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth about the NDA submission was revealed [5]. - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate [6]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [7].

Core Viewpoint - Loncor Gold Inc. is proposing an arrangement with Chengtun Mining Group Co., Ltd. to acquire all issued and outstanding common shares for Cdn$1.38 per share in cash, representing a significant premium over recent trading prices [1][6][11]. Company Overview - Loncor Gold Inc. is a Canadian gold exploration company focused on the Ngayu Greenstone Gold Belt in the Democratic Republic of the Congo, with a resource base that includes an indicated mineral resource of 1.88 million ounces of gold and an inferred mineral resource of 2.09 million ounces of gold [12]. Transaction Details - The arrangement requires shareholder approval at a special meeting scheduled for December 11, 2025, with a minimum of 66 2/3% of votes needed for approval [3][11]. - The proposed cash consideration of Cdn$1.38 per share represents a premium of approximately 48% to the 60-day volume weighted average trading price, 33% to the 30-day VWAP, and 16% to the closing price as of October 10, 2025 [6][7]. - Approximately 37% of currently issued shares have signed voting support agreements in favor of the arrangement [5]. Approval Process - The arrangement must also receive approval from the Ontario Superior Court of Justice, which will assess the fairness and reasonableness of the transaction [4][11]. - Following the completion of the arrangement, Loncor's shares will be delisted from the Toronto Stock Exchange and other exchanges, and the company will cease to be a reporting issuer in Canada and the United States [11]. Strategic Rationale - The all-cash offer provides certainty of value and immediate liquidity to shareholders, while eliminating future dilution and execution risks [15].

Core Viewpoint - Rosen Law Firm is encouraging investors of James Hardie Industries plc to secure legal counsel before the December 23, 2025 deadline for a securities class action lawsuit related to misleading statements about the company's performance during a specific period [2][4]. Group 1: Class Action Details - The class action pertains to investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - The lawsuit alleges that James Hardie misled investors regarding the strength of its North America Fiber Cement segment, falsely claiming that demand was strong and inventory levels were normal, despite knowledge of distributor destocking [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [5].

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2025) - Rusoro Mining Ltd. (TSXV: RML) (the "Company" or "Rusoro") announces that the Delaware Court of Chancery, following a hearing earlier today, denied Gold Reserve's request for expedited treatment of its motion for a preliminary injunction. Specifically, Vice Chancellor Lori Will found that Gold Reserve had failed to make an adequate showing that the continuation of the sale process before the federal court in Delaware poses a risk of irrepa ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [2][5]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [6]. Group 2: Market Reaction - Following the release of a report by NINGI Research on August 5, 2025, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [7]. Group 3: Legal Proceedings - The role of the lead plaintiff in the class action is designated for the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [8]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct to come forward, including whistleblowers and former employees [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In CarMax To Contact Him Directly To Discuss Their OptionsIf you suffered losses in CarMax between June 20, 2025 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13, 2025) - Faruqi & Far ...